Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is approved by the USDA for the treatment of bovine infectious disease. Amplimune is recommended as a one-time immunotherapeutic treatment for the reduction of clinical signs and mortality associated with enterotoxigenic Escherichia coli (ETEC) K99 diarrhea in neonatal calves. Colibacillosis caused by ETEC K99 is one of the principal causes of neonatal calf diarrhea. ETEC infection occurs most frequently in the first week of life, before the calf can become resistant to the disease. Studies have shown that a single, 1 mL dose of Amplimune can induce an immediate innate immune response in the neonatal calf to minimize and control the damage caused by pathogenic E. coli. Therefore, the calf’s ability to overcome the disease challenge is greatly enhanced. As an alternative to antibiotics, Amplimune, with or without fluid therapy, is effective against colibacillosis.
Amplimune is a one-time immunotherapeutic treatment for calves 1 to 5 days old. Amplimune is used to reduce mortality and clinical signs associated with calf scours caused by E. coli K99. Administer 1 ml intravenously.